Scarica l'app Stockscreener
85.60
1.11%
-0.96
Dopo l'orario di chiusura:
85.60
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$86.56
Aprire:
$86.39
Volume 24 ore:
1.52M
Relative Volume:
0.86
Capitalizzazione di mercato:
$16.72B
Reddito:
$4.58B
Utile/perdita netta:
$870.87M
Rapporto P/E:
19.45
EPS:
4.4
Flusso di cassa netto:
$945.58M
1 W Prestazione:
-0.44%
1M Prestazione:
+9.20%
6M Prestazione:
+20.92%
1 anno Prestazione:
+37.49%
Intervallo 1D:
$85.32
$87.35
Intervallo di 1 settimana:
$85.06
$87.99
Portata 52W:
$53.56
$87.99
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Confronta INCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
85.60 | 16.90B | 4.58B | 870.87M | 945.58M | 4.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.48 | 101.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
482.13 | 59.64B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.53 | 59.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
767.00 | 47.00B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
351.13 | 38.12B | 3.81B | -644.79M | -669.77M | -6.24 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Iniziato | Barclays | Overweight |
| 2025-06-16 | Aggiornamento | Stifel | Hold → Buy |
| 2025-03-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Iniziato | UBS | Neutral |
| 2024-10-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-01 | Iniziato | Wolfe Research | Outperform |
| 2024-09-18 | Downgrade | Truist | Buy → Hold |
| 2024-07-02 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Iniziato | Deutsche Bank | Hold |
| 2024-04-23 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Iniziato | Jefferies | Buy |
| 2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-11-21 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-25 | Iniziato | Citigroup | Buy |
| 2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Iniziato | Piper Sandler | Overweight |
| 2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
| 2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Iniziato | Truist | Buy |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-06-16 | Iniziato | The Benchmark Company | Hold |
| 2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Ripresa | William Blair | Outperform |
| 2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Ripresa | BofA/Merrill | Neutral |
| 2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
| 2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-10-03 | Iniziato | Mizuho | Buy |
| 2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Iniziato | Credit Suisse | Neutral |
| 2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Iniziato | Stifel | Hold |
| 2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
Incyte (INCY) Rating Affirmed with Increased Price Target by B o - GuruFocus
Can trapped investors hope for a rebound in Incyte CorporationTrade Ideas & Technical Pattern Based Signals - Newser
Is Incyte Corporation forming a bullish divergence2025 Momentum Check & Capital Protection Trade Alerts - خودرو بانک
Incyte’s Pipeline And Profits Shine Despite Patent Uncertainty - Finimize
Does Incyte Corporation stock benefit from AI growthTrade Ideas & Weekly High Potential Stock Alerts - خودرو بانک
Will Incyte Corporation outperform the market2025 Price Targets & Weekly Stock Breakout Alerts - Newser
Technical signs of recovery in Incyte Corporation2025 Trade Ideas & Verified Short-Term Plans - Newser
Using economic indicators to assess Incyte Corporation potentialQuarterly Earnings Summary & Low Risk Entry Point Guides - Newser
Is Incyte Corporation stock reversal real or fake2025 Winners & Losers & Long-Term Growth Plans - Newser
Is Incyte Corporation showing insider buyingDividend Hike & Consistent Income Trade Recommendations - خودرو بانک
Incyte Corp EVP Sheila Denton Buys, Sells Shares on 2025-09-02 - AInvest
Incyte at Wells Fargo Conference: Strategic Growth Plans - Investing.com
What indicators show strength in Incyte CorporationJuly 2025 Technicals & Daily Entry Point Alerts - Newser
Using portfolio simulators with Incyte Corporation includedMarket Activity Recap & Long-Term Growth Portfolio Plans - Newser
Myelofibrosis Market is Going to Grow at a CAGR of 9% in the Next Ten Years (2025-2034) | DelveInsight - sg.finance.yahoo.com
How to build a custom watchlist for Incyte CorporationLong Setup & Expert Approved Momentum Trade Ideas - Newser
Combining price and volume data for Incyte CorporationRecession Risk & Accurate Buy Signal Notifications - Newser
Incyte at Cantor Global Healthcare Conference: Strategic Growth Beyond 2029 - Investing.com
Incyte launches educational campaign to raise awareness of HS - Investing.com
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa - Financial Times
Should you wait for a breakout in Incyte CorporationShare Buyback & Scalable Portfolio Growth Ideas - Newser
Should I invest in Incyte Corporation before earnings2025 Historical Comparison & High Return Stock Watch Alerts - خودرو بانک
Quantitative breakdown of Incyte Corporation recent moveTreasury Yields & Daily Chart Pattern Signal Reports - Newser
What candlestick patterns are forming on Incyte CorporationWeekly Trend Recap & Step-by-Step Swing Trade Plans - Newser
What Fibonacci levels say about Incyte Corporation rebound2025 Big Picture & Long-Term Growth Stock Strategies - Newser
Will breakout in Incyte Corporation lead to full recoveryCPI Data & Proven Capital Preservation Methods - Newser
Cholangiocarcinoma Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
Incyte (INCY) Stock Is Up, What You Need To Know - Yahoo Finance
Advanced analytics toolkit walkthrough for Incyte CorporationJuly 2025 WrapUp & Verified Chart Pattern Signals - Newser
Applying Elliott Wave Theory to Incyte CorporationAnalyst Upgrade & Smart Allocation Stock Tips - Newser
Incyte Corporation stock hits 52-week high at 87.27 USD - Investing.com
What’s the recovery path for long term holders of Incyte CorporationJuly 2025 Opening Moves & Technical Pattern Alert System - Newser
Reversal indicators forming on Incyte Corporation stockWeekly Market Outlook & Intraday High Probability Setup Alerts - Newser
Can Incyte Corporation disrupt its industry2025 Short Interest & Safe Capital Growth Tips - khodrobank.com
What institutional flow reveals about Incyte CorporationJuly 2025 Big Picture & Trade Opportunity Analysis - Newser
How sentiment analysis helps forecast Incyte CorporationBull Run & Fast Exit/Entry Strategy Plans - Newser
Long term hold vs stop loss in Incyte CorporationJuly 2025 Catalysts & Weekly Setup with ROI Potential - Newser
Will Incyte Corporation stock recover after recent dropDividend Hike & Growth Oriented Trading Recommendations - Newser
Did Incyte's (INCY) Leadership Shift and Pipeline Milestones Just Reshape Its Investment Narrative? - Yahoo Finance
Can technical indicators confirm Incyte Corporation’s reversalPortfolio Risk Summary & Expert Curated Trade Setup Alerts - Newser
How institutional ownership impacts Incyte Corporation stockJuly 2025 Chart Watch & Advanced Technical Analysis Signals - Newser
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Incyte Corp Azioni (INCY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Denton Sheila A. | EVP & General Counsel |
Sep 02 '25 |
Sale |
84.97 |
598 |
50,812 |
33,200 |
1.96%
0.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):